SCHEMBL26111158

SCHEMBL26111158

CC1CC(Oc2ccc(-c3c(C4=CCC5(CC4)CCN(C=CC=O)CC5)n(C)c4ncnc(N)c34)cn2)C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26108721 0.94 KCNH2 (0.33) —
SCHEMBL26109064 0.92 FLT3 (0.34) —
SCHEMBL26108662 0.92 FLT3 (0.34) —
SCHEMBL26107996 0.90 ITK (0.35) —
SCHEMBL26109498 0.87 FGFR1 (0.31) —
SCHEMBL30582574 0.86 ITK (0.40) —
SCHEMBL26106008 0.85 ITK (0.35) —
SCHEMBL26109846 0.84 KCNH2 (0.36) —
SCHEMBL26108120 0.83 LRRK2 (0.32) —
SCHEMBL26108781 0.83 BTK (0.35) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023192502-A1 SPIROBICYCLIC COMPOUNDS ACERAND THERAPEUTICS (USA) LIMITED (US) 2023-10-05 — — WO disclosed
Send feedback